Symbiotec Pharmalab
BSE 544889
4 stories, newest first.
- Revised Reg 31 disclosure: re-creation of pledge on promoter shares; lender and trustee named
- Subsidiary Knovea signs exclusive US commercialization pact for two Dual Chamber Vial injectables
- US FDA issues EIR with VAI classification for Pithampur (SEZ) facility
- Q1 FY27 earnings call transcript: API core, new biotech CDMO and complex injectables verticals
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.